Generics Need Sword, Shield For 'Exceptional' Patent Case

Read the full article (PDF) > 

Generic drug companies marketing in the U.S. have particularly rough going these days. The year 2013 saw substantial new Generic Drug User Fee Amendments "user fees" levied on generics for access to the U.S.Food and Drug Administration. The same year brought the U.S. Supreme Court’s Actavis decision: Now the Federal Trade Commission can sue generics for structuring pharma litigation settlements such that the generic company receives something of value from the brand.

All Content © 2003‐2014, Portfolio Media, Inc.

The articles on our Website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice.